Daiichi Sankyo extends MDS clinical alliance
This article was originally published in Scrip
Executive Summary
Daiichi Sankyohas extended to 2011 its agreement with MDS Pharma Services for the conduct of clinical studies in the US. The partners have completed 100 studies since the alliance was struck in 2002, mostly early-stage work conducted at the Japanese firm's dedicated clinical pharmacology unit within MDS's facility in New Jersey. Work at the 40-bed unit is overseen by Daiichi Sankyo's pharma development operation and supported by staff of the US contract research organisation.